AUTHOR=Liu Cheng-Sen , Song Ying-Qiu , Wang Run-Ze , Wang Zheng , He Rong , Xu Ke , Wang Chen-Yu , Wu Yu , Wang Ye , Zhang Xiao-fang , Li Guang , Wang Tian-Lu 

TITLE=Thorax radiotherapy using 18F-positron emission tomography/computed tomography-guided precision radiotherapy is a prognostic factor for survival in patients with extracranial oligometastatic non-small cell lung cancer:A two-center propensity score-matched analysis

JOURNAL=Frontiers in Oncology

VOLUME=12

YEAR=2022

URL=https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2022.991378

DOI=10.3389/fonc.2022.991378

ISSN=2234-943X

ABSTRACT=<sec><title>Background</title><p>This retrospective study compared positron emission tomography (PET)/computed tomography (CT) and CT in the treatment of extracranial oligometastatic non-small-cell lung cancer (NSCLC) and explored the impact of thorax radiotherapy (TRT) on patient survival.</p></sec><sec><title>Methods</title><p>We reviewed the medical records of Chinese patients with stage IV extracranial oligometastatic NSCLC who underwent PET/CT or CT at two centers. Propensity score matching (PSM) was used to control differences in patient characteristics between the maintenance chemotherapy alone and TRT plus maintenance chemotherapy groups.</p></sec><sec><title>Results</title><p>We analyzed 192 eligible patients. The median survival time was better in patients who received PET/CT than in those who only received CT (n = 192, 16 months vs. 6 months, <italic>p</italic>&lt;0.001). Subgroup analysis showed the median survival time was significantly longer in the TRT plus maintenance group than in the chemotherapy alone group in patients who underwent PET/CT examinations (n = 94, 25 months vs. 11 months, <italic>p</italic>&lt;0.001). However, there was no statistical difference in survival between both groups in patients who underwent CT examinations (n = 98, 8 months vs. 5 months, <italic>p</italic> = 0.180). A multifactorial analysis revealed a more favorable prognosis in patients who underwent PET/CT evaluation (HR: 0.343, 95% CI: 0.250-0.471, <italic>p &lt;</italic>0.001) and TRT (HR: 0.624, 95% CI: 0.464-0.840, <italic>p</italic> = 0.002), than in those who did not. PSM was consistent with these results.</p></sec><sec><title>Conclusions</title><p>PET/CT-guided TRT is associated with improved clinical outcomes in patients with stage IV extracranial oligometastatic NSCLC.</p></sec>